Journals / Turkish Journal of Medical Sciences / 2012 / Cilt: 42 - Sayı: 6

Hyaluronidase-1 expression is not a predictor of biochemical recurrence in radical prostatectomy specimens

Pages
1020–1027
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further molecular markers and genetic studies are necessary to predict the biochemical recurrence after radical prostatectomy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purposes of this study were to evaluate the rate of biochemical recurrence among patients who underwent radical prostatectomy due to localized prostate cancer, assess the risk factors of biochemical recurrence, and investigate its relation with hyaluronidase-1 (HYAL-1).
📊
Key Findings & Data:Materials and methods: We retrospectively evaluated the data of 112 patients who underwent radical retropubic prostatectomy.
💡
Conclusion & Impact:Further molecular markers and genetic studies are necessary to predict the biochemical recurrence after radical prostatectomy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Key words: Prostate · prostate cancer · recurrence

Abstract

The purposes of this study were to evaluate the rate of biochemical recurrence among patients who underwent radical prostatectomy due to localized prostate cancer, assess the risk factors of biochemical recurrence, and investigate its relation with hyaluronidase-1 (HYAL-1). Materials and methods: We retrospectively evaluated the data of 112 patients who underwent radical retropubic prostatectomy. HYAL-1 expression was evaluated immunohistochemically and staining was graded as mild, moderate, and severe. Two blinded pathologists evaluated the specimens. The relation among preoperative pathologic findings that were detected in transrectal ultrasound (TRUS) guided biopsy, specimens of radical prostatectomy in the final stage, and biochemical recurrence rate were also evaluated. Mean follow-up time was 59.8 months (range: 20 to 92 months). Results: Tumor recurrence was detected in 29 patients. There was no relation between HYAL-1 expression and recurrence. In multivariate analysis, the percentage of tumors detected in TRUS biopsy specimens, positive surgical margin, capsular involvement, and seminal vesicle invasion detected in the final pathology were correlated with recurrence. The sensitivity, specificity, positive predictive value, and negative predictive value of HYAL-1 expression were respectively 38%, 63%, 30%, and 71%. Conclusion: HYAL-1 expression was not found to be predictive for recurrence. Further molecular markers and genetic studies are necessary to predict the biochemical recurrence after radical prostatectomy.

Özet

The purposes of this study were to evaluate the rate of biochemical recurrence among patients who underwent radical prostatectomy due to localized prostate cancer, assess the risk factors of biochemical recurrence, and investigate its relation with hyaluronidase-1 (HYAL-1). Materials and methods: We retrospectively evaluated the data of 112 patients who underwent radical retropubic prostatectomy. HYAL-1 expression was evaluated immunohistochemically and staining was graded as mild, moderate, and severe. Two blinded pathologists evaluated the specimens. The relation among preoperative pathologic findings that were detected in transrectal ultrasound (TRUS) guided biopsy, specimens of radical prostatectomy in the final stage, and biochemical recurrence rate were also evaluated. Mean follow-up time was 59.8 months (range: 20 to 92 months). Results: Tumor recurrence was detected in 29 patients. There was no relation between HYAL-1 expression and recurrence. In multivariate analysis, the percentage of tumors detected in TRUS biopsy specimens, positive surgical margin, capsular involvement, and seminal vesicle invasion detected in the final pathology were correlated with recurrence. The sensitivity, specificity, positive predictive value, and negative predictive value of HYAL-1 expression were respectively 38%, 63%, 30%, and 71%. Conclusion: HYAL-1 expression was not found to be predictive for recurrence. Further molecular markers and genetic studies are necessary to predict the biochemical recurrence after radical prostatectomy.

🔖

Cite This Article

ZEMHERİ, I. E., YILDIRIM, A., GÜRBÜZ, M. C., GÜNER, B., ÇAŞKURLU, T., ÖZKANLI, S. Ş. (2022). Hyaluronidase-1 expression is not a predictor of biochemical recurrence in radical prostatectomy specimens. Turkish Journal of Medical Sciences, Cilt: 42 - Sayı: 6, 1020–1027. https://ajindex.com/articles/611149

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Lipponen P, Aaltomaa S, Tammi R, Tammi M, Agren U, Kosma VM. High stromal hyaluronan is associated with poor diff erentiation and metastasis in prostate cancer. Eur J Cancer 2001; 37: 849-56.
  2. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johannson R et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000; 156: 529-36. 6. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 1998; 58: 342-7.
  3. Hautmann SH, Lokeshwar VB, Schroeder GL, Civantos F, Duncan RC, Gnann R et al. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol 2001; 165: 2068-74.
  4. Lokeshwar VB, Obek C, Soloway MS. Tumor-associated hyaluronan: a new and sensitive and specifi c urine marker for bladder cancer. Cancer Res 1997; 57: 773-7. 9. Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen J, Johannson R et al. Prognostic value of hyaluronan expression in non-small-lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 2001; 95: 12-27.
  5. Anttila MA, Tammi R, Tammi M. High levels of stromal HA predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000; 60: 150-5. Toole BP. Proteoglycans and hyaluronan in morphogenesis and diff erentiation. In: Hey ED, editor. Cell biology of extracellular matrix, vol. 19. New York: Plenum Press; 1991. p.305-14.
  6. Csoka A, Frost G, Stern R. Th e six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001; 2: 499-508.
  7. Lepperdinger G, Mulleger J, Kreil G. Hyal2 - less active, but more versatile? Matrix Biol 2001; 20: 509-14.
  8. Laurent TC, Fraser JRE. Hyaluronan. FASEB J 1992; 6: 2397- 404. Tammi MI, Day AJ, Turley E. Hyaluronan and homeostasis: a balancing act. J Biol Chem 2002; 277: 4581-4.
  9. Paiva P, Van Damme MP, Tellbach M, Jones RL, Jobling T, Salamonsen LA. Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecol Oncol 2005; 98: 193-202.
  10. Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001; 276: 11922-32.
  11. Kosaki R, Watanabe K, Yamaguchi Y. Overprod